Interactive Investor
>>

Adaptimmune Therapeutics ADR (NASDAQ:ADAP) Share Price

ADAP

Adaptimmune Therapeutics ADR

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

 / 

- / -
-
- / -
-
-
-

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.

NASDAQ:ADAP

US00653A1079

USD

Loading...

Loading Comparison

Latest ADAP News